Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

It's draft month, and there's one Clemson Tiger who could be rising up every team's draft board until everybody's name is called. Now, that agenda might be changing. In a metric titled “relative ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...

RPSC RAS mains 2025 result: The Rajasthan Public Service Commission (RPSC) has officially released the RPSC RAS mains result 2025. Candidates who appeared for the mains examination can now access ...